Inventor · disambiguated record
Christopher G. Nasveschuk
Also filed as: NASVESCHUK CHRISTOPHER · NASVESCHUK CHRISTOPHER G
58 granted patents·22 pending applications·296 citations·filing 2011–2025
98Inventor score
Files withC4 THERAPEUTICS INC36CONSTELLATION PHARMACEUTICALS INC14GENENTECH INC12BAYER AG7BROAD INST INC3
Top patents by PatentIndex Score
80 records- 0197US11584748B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Feb 21, 2023·11 cites·11 claims
- 0297US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0397US9469646B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2015·Granted Oct 18, 2016·21 cites·4 claims
- 0497US9249161B2Bromodomain inhibitors and uses thereofALBRECHT BRIAN K·Filed 2011·Granted Feb 2, 2016·50 cites·12 claims
- 0596US11623929B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Apr 11, 2023·7 cites·20 claims
- 0696US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0796US9409865B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2015·Granted Aug 9, 2016·14 cites·3 claims
- 0895US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0995US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 1094US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1193US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 1293US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1393US11691972B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2021·Granted Jul 4, 2023·5 cites·10 claims
- 1493US11492358B1Macrocyclic indole derivativesBAYER AG·Filed 2021·Granted Nov 8, 2022·3 cites·18 claims
- 1593US9085583B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION—PHARMACEUTICALS INC·Filed 2013·Granted Jul 21, 2015·18 cites·14 claims
- 1692US10981932B2Macrocyclic indole derivativesBAYER AG·Filed 2017·Granted Apr 20, 2021·9 cites·17 claims
- 1792US9051269B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2012·Granted Jun 9, 2015·9 cites·7 claims
- 1892US8796261B2Bromodomain inhibitors and uses thereofALBRECHT BRIAN K·Filed 2011·Granted Aug 5, 2014·21 cites·28 claims
- 1991US9371331B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2015·Granted Jun 21, 2016·8 cites·9 claims
- 2091US9206128B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2012·Granted Dec 8, 2015·10 cites·17 claims
- 2190US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 2290US11891404B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2022·Granted Feb 6, 2024·1 cites·10 claims
- 2389US12157735B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Dec 3, 2024·1 cites·23 claims
- 2488US12152041B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2022·Granted Nov 26, 2024·1 cites·6 claims
- 2588US12049464B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·11 claims
- 2687US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 2787US11440923B2Substituted macrocyclic indole derivativesBAYER AG·Filed 2018·Granted Sep 13, 2022·3 cites·15 claims
- 2887US10308614B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jun 4, 2019·4 cites·21 claims
- 2987US9745305B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted Aug 29, 2017·11 cites·17 claims
- 3087US9522920B2Bromodomain inhibitors and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted Dec 20, 2016·10 cites·21 claims
- 3186US11478451B1Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Oct 25, 2022·3 cites·16 claims
- 3286US11401278B2Macrocyclic indole derivativesBROAD INST INC·Filed 2018·Granted Aug 2, 2022·3 cites·13 claims
- 3386US10016405B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted Jul 10, 2018·3 cites·4 claims
- 3485US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 3585US11447504B2Macrocyclic chlorine substituted indole derivativesBAYER AG·Filed 2018·Granted Sep 20, 2022·3 cites·14 claims
- 3685US11286263B2Macrocyclic fluorine substituted indole derivativesBROAD INST INC·Filed 2018·Granted Mar 29, 2022·3 cites·9 claims
- 3785US9980952B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·3 cites·8 claims
- 3885US9969716B2Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted May 15, 2018·4 cites·21 claims
- 3983US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4083US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4181US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 4281US11753397B2Cereblon binders for the degradation of ikarosC4 THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 4381US2025084081A1Compounds for targeted degradation of brd9C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4480US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 4580US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4679US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 4779US12227504B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Granted Feb 18, 2025·0 cites·13 claims
- 4879US10183009B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jan 22, 2019·3 cites·22 claims
- 4979US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 5079US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →